Read by QxMD icon Read


Horacio A Capote, Michelle Rainka, Erica S Westphal, Jonathan Beecher, Francis M Gengo
PURPOSE: To determine the effects of ropinirole on manic switching and disease severity in bipolar disorder. DESIGN AND METHODS: A cross-sectional survey was conducted in 23 bipolar depressed patients using ropinirole combination therapy (Young Mania Rating Scale [YMRS], Bipolar Inventory of Symptoms Scale [BISS]). Retrospective Clinical Global Impression of Change (CGI-C) and CGI-S (Severity) were captured via chart review. FINDINGS: One patient (4...
January 20, 2017: Perspectives in Psychiatric Care
Kirti Vishwakarma, Juhi Kalra, Ravi Gupta, Mukesh Sharma, Taruna Sharma
BACKGROUND: We aimed to compare the efficacy of fixed doses of bupropion and ropinirole and iron alone for the treatment of restless legs syndrome (RLS) and to look for the tolerability of these medications. MATERIALS AND METHODS: Patients diagnosed with RLS were randomly divided into three groups with thirty patients in each group (Group A: Bupropion [300 mg/day], Group B: Ropinirole [0.25-0.5 mg/day], and Group C: Oral iron [150 mg elemental iron] along with folic acid [500 μg])...
October 2016: Annals of Indian Academy of Neurology
Mahyar Etminan, Mohit Sodhi, Ali Samii, Ric M Procyshyn, Michael Guo, Bruce C Carleton
BACKGROUND: Recently, the US Food and Drug Administration issued a warning regarding the potential risk of gambling disorder, but large epidemiologic studies are lacking. METHODS: We used a large health claims database from the United States and conducted a nested case-control study. Cases were defined as subjects newly diagnosed with gambling disorder or impulse control disorder. For each case, 10 controls were selected and matched to cases by age and follow-up time and calendar time...
February 2017: Journal of Clinical Psychopharmacology
John W Winkelman, Melissa J Armstrong, Richard P Allen, K Ray Chaudhuri, William Ondo, Claudia Trenkwalder, Phyllis C Zee, Gary S Gronseth, David Gloss, Theresa Zesiewicz
OBJECTIVE: To make evidence-based recommendations regarding restless legs syndrome (RLS) management in adults. METHODS: Articles were classified per the 2004 American Academy of Neurology evidence rating scheme. Recommendations were tied to evidence strength. RESULTS AND RECOMMENDATIONS: In moderate to severe primary RLS, clinicians should consider prescribing medication to reduce RLS symptoms. Strong evidence supports pramipexole, rotigotine, cabergoline, and gabapentin enacarbil use (Level A); moderate evidence supports ropinirole, pregabalin, and IV ferric carboxymaltose use (Level B)...
December 13, 2016: Neurology
Prince Muhammad Kashif, Asadullah Madni, Muhammad Ashfaq, Mubashar Rehman, Muhammad Ahmad Mahmood, Muhammad Imran Khan, Nayab Tahir
The current study aimed to develop novel pH independent microparticles loaded with ropinirole (ROP) for sustained drug release. Eudragit RS 100 was used as release retardant and microparticles were fabricated by oil-in-oil emulsion solvent evaporation method. A three-factor three-level Box-Behnken design using Design-Expert software was employed to optimize formulation variables. Ropinirole loaded microparticles were evaluated with respect to morphology, particle size, encapsulation efficiency, and in vitro release profile...
November 9, 2016: AAPS PharmSciTech
Seerapani Gopaluni, Mohamed Sherif, Naim A Ahmadouk
BACKGROUND: Restless legs syndrome (RLS) is defined as the spontaneous movement of the limbs (mainly legs) associated with unpleasant, sometimes painful sensation which is relieved by moving the affected limb. Prevalence of RLS among people on dialysis has been estimated between 6.6% and 80%. RLS symptoms contribute to impaired quality of life and people with RLS are shown to have increased cardiovascular morbidity and mortality.Various pharmacological and non-pharmacological interventions have been used to treat primary RLS...
7, 2016: Cochrane Database of Systematic Reviews
John W Winkelman, Susan E Mackie, Leslie A Mei, Samuel Platt, Laura Schoerning
BACKGROUND: We examined the short- and long-term efficacy and tolerability of a cross-titration algorithm from oral dopamine agonists to the rotigotine transdermal patch in patients dissatisfied with their restless legs syndrome (RLS) treatment, predominantly with mild augmentation. METHODS: Patients with RLS (n = 20) were recruited at a single site. The cross-titration consisted of decreasing oral dopaminergic agents (ropinirole by 1 mg or pramipexole by 0...
August 2016: Sleep Medicine
François Montastruc, Florence Moulis, Mélanie Araujo, Leila Chebane, Olivier Rascol, Jean-Louis Montastruc
PURPOSE: Some studies have suggested a potential risk of heart failure in patients with Parkinson's disease receiving dopamine (DA) agonists. However, the results are conflicting. We used VigiBase®, the World Health Organization (WHO) Global Individual Case Safety Reports (ICSRs) database, to investigate a potential signal strengthening of heart failure with DA agonists in Parkinsonian patients older than 45 years. METHODS: A case/non-case (disproportionality) analysis was performed in Vigibase® using ICSRs registered between 1978 and May 2016...
January 2017: European Journal of Clinical Pharmacology
Sofía Negro, Liudmilla Boeva, Karla Slowing, Ana Fernández-Carballido, Luis García-García, Emilia Barcia
A new controlled delivery system is developed for ropinirole (RP) for the treatment of Parkinson´s disease (PD) consisting in PLGA microparticles (MPs) which exhibited in vitro constant release of RP (78.23 µg/day/10 mg MPs) for 19 days. The neuroprotective effects of RP released from MPs are evaluated in SKN-AS cells after exposure to rotenone (20 μM). Cell apoptosis was significantly reduced by RP (100-120 μM). Daily doses of rotenone (2 mg/kg) given i.p. to rats induced neuronal and behavioral changes similar to those of PD...
September 28, 2016: Current Pharmaceutical Design
Ken Ikeda, Takehisa Hirayama, Takanori Takazawa, Kiyokazu Kawabe, Yasuo Iwasaki
Objective Parkinson's disease (PD) is characterized by the progressive degeneration of the nigrostriatal dopaminergic neurons. Rotigotine is a non-ergot dopamine receptor agonist (DA). Its transdermal patch maintains the effective concentrations for 24 hours. Freezing of gait (FOG) is a common and devastating symptom in PD patients. Little is known about therapeutic effects of rotigotine on FOG in PD patients. Herein we compared how three non-ergot DAs of rotigotine, pramipexole LA and ropinirole CR influence FOG, besides classical motor deficits in PD patients...
2016: Internal Medicine
Paul J Cocker, M Tremblay, S Kaur, Catharine A Winstanley
RATIONALE: Whilst dopamine agonist therapies can successfully manage the symptoms of diseases such as Parkinson's disease (PD), fibromyalgia and restless leg syndrome, they can also cause impulse control and addiction disorders such as gambling disorder (GD). These compulsive behaviours seriously undermine the utility of such treatments. OBJECTIVES: The objective of the study was to model this phenomenon using a rodent slot machine task (rSMT) in order to investigate the neurobiological basis underlying such behavioural changes...
January 2017: Psychopharmacology
Michael R Cohen, Judy L Smetzer
These medication errors have occurred in health care facilities at least once. They will happen again-perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them at your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the Institute for Safe Medication Practices (ISMP) Medication Errors Reporting Program...
September 2016: Hospital Pharmacy
Monica Rao, Deepak Kumar Agrawal, Chaitanya Shirsath
Parkinson's disease is a degenerative disorder of the central nervous system. The most obvious symptoms are movement-related such as shaking, rigidity, slowness of movement and difficulty with walking, rigid muscular movements and difficulty in chewing and swallowing especially solid dosage forms. Ropinirole is an anti-Parkinson drug which has low oral bioavailability which is primarily due to first pass metabolism. The objective of proposed work was to increase bioavailability of Ropinirole and avoid patient discomfort by formulating thermoreversible in situ nasal gel...
August 17, 2016: Drug Development and Industrial Pharmacy
Xingjin Yan, Shouwei Zhao, Wenwen Zhu, Jing Rao, Li Kang, Jiaqiang Xu, Dan Li, Lixia Qin, Lihui Qiu, Gao Li, Jiangeng Huang, Luqin Si
AIM: To adequately support PK evaluation of ropinirole in rats following intranasal administration, it was desirable to determine ropinirole concentrations in rat plasma, brain homogenate and microdialysate. Results & methodology: A robust LC-MS/MS method has been developed for the determination of ropinirole in biological samples. Liquid-liquid extraction using ethyl acetate eliminated matrix effect due to significantly reduced levels of lysoglycerophosphocholines. The assay was fully validated with dynamic ranges of 0...
September 2016: Bioanalysis
Melanie Tremblay, Mason M Silveira, Sukhbir Kaur, Jay G Hosking, Wendy K Adams, Christelle Baunez, Catharine A Winstanley
D2/3 receptor agonists are effective treatments for Parkinson's disease (PD), but can precipitate impulse control disorders (ICDs) including gambling disorder (GD). The neurobiological mechanisms underlying this devastating side-effect of dopamine agonist replacement therapy (DRT), and any dependence on the dopamine depletion caused by PD, are unclear. It is also unclear whether previous biases towards risk or uncertainty are a risk factor for developing these ICDs. We investigated whether chronic D2/3 agonist administration (5 mg/kg/day ropinirole for 28 days) altered performance of a rat model of gambling-like behaviour, the rodent betting task (rBT), and examined if baseline behaviour predicted this behavioural change...
January 2017: European Journal of Neuroscience
Małgorzata Michałowska, Urszula Fiszer, Tomasz Szatanowski
UNLABELLED: Chronic treatment with levodopa in Parkinson's disease (PD) is associated with the risk of development of motor fluctuations and dyskinesias, i.e. motor levodopa-induced complications (MLIC). AIM: The aim of the study was to investigate factors influencing prevalence of MLIC in PD patients. MATERIALS AND METHODS: 76 patients with idiopathic PD were included in the study. Theirs mean disease duration was 10,33 years and mean levodopa therapy duration was 8,65 years...
June 2016: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
Phyllis J Kuhn, Daniel J Olson, John P Sullivan
CONTEXT: Restless legs syndrome (RLS) treatments have included medications with many adverse effects and limited utility. A noninvasive device would potentially have extensive use where RLS medications may not be appropriate, such as in pregnant or breastfeeding women, people with mild RLS, people who operate machinery or drive occupationally, people with severely impaired renal function, or people who are taking medications contraindicated with RLS medications. OBJECTIVE: To assess the efficacy and safety of a device that produces targeted pressure on the abductor hallucis and the flexor hallucis brevis muscles to reduce the symptoms of moderate to severe RLS, and to compare the current findings with findings from studies of ropinirole use in patients with primary RLS...
July 1, 2016: Journal of the American Osteopathic Association
Nathan A Holtz, Stephanie E Tedford, Amanda L Persons, Salvatore A Grasso, T Celeste Napier
Pramipexole and ropinirole are dopamine agonists that are efficacious in treating motor disturbances of neuropathologies, e.g., Parkinson's disease and restless legs syndrome. A significant portion of treated patients develop impulsive/compulsive behaviors. Current treatment is dose reduction or switching to an alternative dopamine replacement, both of which can undermine the motor benefits. Needed is a preclinical model that can assist in identifying adjunct treatments to dopamine agonist therapy that reduce impulsive/compulsive behaviors without interfering with motor benefits of the dopamine agonist...
October 3, 2016: Progress in Neuro-psychopharmacology & Biological Psychiatry
Yuji Shiga, Yuhei Kanaya, Ryuhei Kono, Shinichi Takeshima, Yutaka Shimoe, Masaru Kuriyama
We report the patient of a 53-year-old woman who developed subacute-onset marked tonge protrusion and bite. She was diagnosed as dementia with Lewy bodies (DLB) from the clinical features including progressive cognitive decline, visual hallucinations, parkinsonism, and severe insomnia and depression, and the radiological finding of low dopamine transported uptake in basal ganglia by Dat SCAN and low blood circulation in occipital lobe of cerebrum. The patient received 600 mg doses of levodopa for over a year, followed by rotigotine and ropinirole with a rapid increase of dosage...
June 22, 2016: Rinshō Shinkeigaku, Clinical Neurology
A Rizos, A Sauerbier, A Antonini, D Weintraub, P Martinez-Martin, B Kessel, T Henriksen, C Falup-Pecurariu, M Silverdale, G Durner, K Røkenes Karlsen, M Grilo, P Odin, K Ray Chaudhuri
BACKGROUND AND PURPOSE: Impulse control disorders (ICDs) in Parkinson's disease (PD) are associated primarily with dopamine agonist (DA) use. Comparative surveys of clinical occurrence of impulse control behaviours on longer acting/transdermal DA therapy across age ranges are lacking. The aim of this study was to assess the occurrence of ICDs in PD patients across several European centres treated with short- or long-acting [ropinirole (ROP); pramipexole (PPX)] and transdermal [rotigotine skin patch (RTG)] DAs, based on clinical survey as part of routine clinical care...
August 2016: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"